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Abstract: Skin is the first barrier preventing microorganism
invasion in host. Wounds destroy this defense barrier and,
without an appropriate care, may lead to sepsis. Neutrophil
activation and immigration plays an important role at the
inflammatory stage of wound healing. Neutrophils are known to
express proteinase-activated receptors (PARs), which can be
activated by serine proteases, also by enzymes involved in wound
healing. We previously reported that PAR2 agonists up-regulate
cell adhesion molecule expression and cytokine production by
human neutrophils. Here, we demonstrate that PAR2 agonists
(serine proteases as well as synthetic peptides) reduce
transendothelial migration of neutrophils and prolong their life
in vitro. Synthetic PAR2 agonist also enhanced protective
interferon (IFN)c-induced FccRI expression at neutrophil cell
surface. Of note, IFNc is a cytokine, which was used in clinical
trials to reactivate human neutrophil functions during sepsis.
Moreover, we observed a significant increase of PAR2 expression
on cell surface of neutrophils from septic patients as compared
with healthy volunteers. Together, our results indicate that PAR2
may be involved in the pathophysiology of neutrophil-endothelial
interactions during wound healing or later during sepsis in
humans, potentially by affecting neutrophil apoptosis,
transendothelial migration and Fcc receptor-mediated
phagocytosis.
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Introduction
Proteinase-activated receptor-2 (PAR2) is the second mem-
ber of a novel G protein-coupled receptor subfamily with a
unique mechanism of receptor activation. Accessible serine
proteases cleave the receptor to expose a new, previously
cryptic, N-terminal sequence, which serves further as a
‘tethered’ receptor-activating ligand. To date, four PARs
are known [reviewed in Refs. (1,2)]. A variety of serine
proteinases, including members of the trypsin family, mast
cell tryptase, immune cell-derived or microorganism-
derived enzymes activate PAR2 (3–8). Functional PAR2 is
expressed by cells involved in inflammatory and allergic
responses such as mast cells, dendritic cells, eosinophils,
macrophages and neutrophils (9–14). However, the ability
of PAR2 agonists to act on key neutrophil features such as
phagocytosis, apoptosis or transmigration through the
Abbreviations: FCS, fetal calf serum; fMLP, N-formylmethionyl-
leucyl-phenylalanine; HMEC-1, human microvascular endothelial
cells; HUVEC, human umbilical vein endothelial cells; IFNc,
interferon gamma; PAR2, proteinase-activated receptor-2; PMN,
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endothelium is still uninvestigated. Nonetheless, PAR2
immunoreactivity can be found on neutrophils during
inflammation or delayed wound healing, for example.
Thus, PAR2 may be involved in wound healing (inflam-
matory stage) or in further progression of inflammation
of untreated wounds, which in very serious cases leads to
sepsis.
Recent studies indicated an important role for PAR2
activation in the development of arthritis, acute pancreati-
tis, airway inflammation, atopic dermatitis, and encephalo-
myelitis (2,15,16). In some cases, PAR2 activation led to
pro-inflammatory effects (17–19), however, under certain
conditions to anti-inflammatory protective effects (20,21).
Changes in main neutrophil functions are known to play a
role in bacteria-induced pathologies (wound infection, sep-
sis or septic shock) as well as in bacteria-induced complica-
tions of skin diseases (22,23). However, the role of PAR2
activation in modulation of neutrophil-endothelial interac-
tion and neutrophil apoptosis during such diseases remains
elusive.
Interferons (IFNc, IFNa) are known to activate protec-
tive functions of human neutrophils and monocytes
(phagocytosis, generation of reactive oxygen species, bacte-
rial killing) (24–27). IFNc was also used in clinical trials in
sepsis for reactivation of monocyte and neutrophil immune
functions (28). However, the ability of PAR2 agonists to
enhance (during combined application) IFNc-induced pro-
tective effects at human neutrophils is still unclear.
Previously (29), we demonstrated that PAR2 agonists
up-regulate the expression of a4b1 and Mac-1 integrins on
neutrophil cell surface, and also enhance the production of
IL-1b, IL-6, IL-8 by human neutrophils (29). These inte-
grins and cytokines are known to affect neutrophil trans-
endothelial migration, apoptosis and phagocytic activity
[reviewed in Refs. (30,31)]. Therefore, we hypothesized that
stimulation of human neutrophils with PAR2 agonists may
act on such key neutrophil features in vitro. To explore
this, we examined whether PAR2 agonists affect: (i) human
neutrophil apoptosis and (ii) neutrophil transendothelial
migration. Further, we investigated the ability of PAR2 ago-
nist to enhance IFNc-induced protective effect at human
neutrophils (expression of Fcc-receptors, which are known
to play crucial role in phagocytic activity of these cells).
Moreover, we determined whether neutrophils of septic
patients show altered PAR2 cell surface expression as com-
pared with cells from healthy volunteers.
Materials and methods
Reagents
Human recombinant interferon-c (IFNc) was obtained from
TebuBio (Offenbach, Germany). Trypsin was purchased
from Sigma (Deisenhofen, Germany). Human b-tryptase was
expressed in Pichia pastoris and used as described (32).
Human PAR2 activating peptide with the sequence
trans-cinnamoyl-LIGRLO-NH2 (tcAP) and reverse peptide
with sequence trans-cinnamoyl-OLRGIL-NH2 (tcRP)
(Dr. McMaster, University of Calgary, Canada) was used
as described previously (29,33). Primary antibodies were:
unconjugated or fluorescein isothiocyanate (FITC)-conju-
gated monoclonal mouse anti-human PAR2 (clone SAM-11)
(Santa Cruz Biotechnology, Heidelberg, Germany);
monoclonal mouse anti-human CD64 (DakoCytomation,
Hamburg, Germany) and secondary antibodies were
PE-conjugated goat anti-mouse from Jackson Immuno-
Research (Hamburg, Germany). The FITC-conjugated mouse
IgG1 isotype control antibodies were from PharMingen
(Hamburg, Germany). Cell culture reagents were from
BioWhittaker (Aachen, Germany), PromoCell (Heidelberg,
Germany), Gibco-Life Technologies (Karlsruhe, Germany),
Sigma, Beckton-Dickenson (Heidelberg, Germany), Falcon
(via Beckton-Dickenson, Heidelberg, Germany), Corning
(Schiphool, the Netherlands).
Isolation and culture of human neutrophils
For sepsis studies, the blood from patients who fulfilled the
clinical criteria for septic shock, was used (34). The study
of patients with septic shock (n = 19) and healthy volun-
teers (n = 18, sex and aged matched) was performed with
the permission of the Independent Ethics Committee of the
University of Ulm (approval No. 82 ⁄ 2002). Exclusion cri-
teria were age <18 years, pregnancy, rapidly progressing
underlying disease, HIV ⁄ AIDS, cardiogenic shock as the
primary underlying disease, underlying haematological dis-
ease, or cytotoxic therapy given within the previous
6 months.
Blood for in vitro experiments with normal human neu-
trophils was obtained from healthy adult human volunteers
in heparinized tubes or in buffy-coats (Deutsches Rotes
Kreuz, Muenster, Germany). Polymorphonuclear neutroph-
ils (PMNs) were isolated using lymphocyte separation med-
ium (equivalent of Percoll produced by PAA Laboratories,
Cölbe, Germany) followed by hypotonic stress to remove
erythrocytes, as described (29,35). Neutrophils were cul-
tured in RPMI 1640 medium supplied with: 1% fetal calf
serum (FCS), 1% penicillin ⁄ streptomycin, 1% l-Glutamine
and 1% non-essential amino acids. After isolation, cells
were cultured (37C, 5%CO2) during 2 h for recovery.
For human neutrophil stimulation, IFNc was used at a
concentration of 200 U ⁄ ml. The same IFNc concentration
was used in all co-stimulation experiments (together with
the PAR2 agonist). For PAR2 stimulation, PAR2-tcAP was
used in a concentration of 1 · 10)4 m. This peptide has
been previously documented to be an effective and specific
PAR2 agonist in PAR2-expressing cells (33), causing effects
identical to a ‘tethered’ ligand agonist like SLIGRL-NH2
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or SLIGKV-NH2. The corresponding reverse peptide
(PAR2-tcRP) also was used in concentration 1 · 10)4 m
and served as negative control. Trypsin and tryptase [tryp-
tase was dissolved in heparin solution, with concentration
of heparin 30 lg ⁄ ml of phosphate-buffered saline (PBS)]
were used in concentration of 1 · 10)7 m. Stimulation with
heparin solution alone (30 lg heparin per millilitre of PBS)
also was used as an additional control.
Transendothelial migration assay
Transmigration assays were performed as described in
details elsewhere (36). Briefly, 2.2 · 105 human microvas-
cular endothelial cells (HMEC)-1 cells were seeded on
fibronectin-coated 6.5-mm Transwell filters (Costar, Boden-
heim, Germany) with a 5-lm pore size, and were grown at
37C and 5%CO2 to confluence. The integrity of the endo-
thelial monolayer was confirmed by Filipin III (Sigma,
cat. 4767) staining followed by fluorescent microscopic
investigation, and, in parallel by the measurement of
transendothelial electric resistance. After 48 h, medium and
non-adherent cells were removed. Immediately, 600 ll of
assay medium together with chemo-attractant IL-8
(25 ng ⁄ ml) was added to the lower compartment of a two-
chamber system separated by the Transwell filters. Assay
medium consisted of Dulbecco’s modified Eagle’s medium
(PAA Laboratories, Cölbe, Germany) supplemented with
10% FCS, 25 mm HEPES, 2% l-glutamine and 100 U ⁄ ml
penicillin ⁄ streptomycin. Always the constant number of
neutrophils was taken for assay. Neutrophils (2 · 106 cells)
in 100-ll assay medium together with stimuli were added
to the upper chamber, and cells were subsequently incu-
bated for 2 h at 37C and 5% CO2. Among stimuli were
either N-formylmethionyl-leucyl-phenylalanine (fMLP) (a
well-known granulocyte activator, used as a positive con-
trol, concentation 5 nm) or PAR2 agonists (mast cell tryp-
tase 10)7 m; trypsin 10)7 m; PAR2-tcAP 1 · 10)4 m) or
PAR2 reverse peptide (PAR2-tcRP 1 · 10)4 m). Experi-
ments were routinely carried out in triplicates.
At the end of the assay, the upper chamber was removed
and the migrated neutrophils in the lower compartment
were collected and quantified in a Casy TT (Schärfe Instru-
ments, Reutlingen, Germany) or Coulter Counter Z2
(Coulter, Krefeld, Germany). Each sample was made in
triplicate. Four independent experiments were performed.
Flow cytometric analysis of CD64 and PAR2 cell
surface expression on neutrophils from healthy
volunteers and septic patients
Briefly, 1 · 106 cells from healthy donors were used for
each analysis. Cells were washed twice in PBS (1%FCS)
and subsequently incubated with primary mouse anti-
human CD64 antibody or with anti-human PAR2 antibody
(in both cases 1 lg ⁄ ml) for 30 min on ice. Then, cells were
washed and further incubated with PE-conjugated goat
anti-mouse (1:50) secondary antibody in PBS (1%FCS) for
additional 30 min on ice. Cells, which were incubated with
secondary antibody alone served as a negative control. At
least 25 000 stained cells were analysed with the FACScali-
bur and Cell Quest Pro Software (Becton Dickinson,
Heidelberg, Germany).
For septic patient studies, whole blood was collected in
an EDTA-containing syringe and erythrocytes were lysed
using 1 · flow cytometric analysis (FACS) lysing solution
(BD PharMingen, San Diego, CA, USA). A total of 10 ll of
FITC-labelled anti-human PAR2 was used for receptor
staining at neutrophil surface (20 min at RT). FITC-
labelled IgG was added for isotype control (negative
control) samples. After washing, the leukocytes were recon-
stituted in a fixing solution (1% paraformaldehyde in
PBS). The purity of granulocytes was estimated with anti-
CD45 ⁄ anti-CD14 (to exclude monocyte contamination
among analysed cells). At least 20 000 stained neutrophils
from each donor in both groups were analysed with
the FACScalibur and Cell Quest Pro Software (Becton
Dickinson).
Annexin-V staining assay
Labelling of apoptotic neutrophils with annexin-V-FITC
(37) and counterstaining with propidium iodide for necro-
tic cells (Annexin V-FITC Apoptosis Detection kit, BD
PharMingen) were performed according to manufacturer’s
instructions. Labelled neutrophils were analysed by flow
cytometry using FACScalibur and Cell Quest Pro software
(Becton Dickinson).
Statistical analysis
Results are expressed as mean ± SEM. At least three inde-
pendent experiments have been performed (n > 3). Statisti-
cal evaluation was performed by an analysis of variance
and Student’s t-test. Significance was assigned where
P < 0.05.
Results
Proteinase-activated receptor-2 agonist stimulation
reduces the transendothelial migration of human
neutrophils in vitro
Neutrophil-endothelial interactions play a crucial role in
the pathophysiology of various skin diseases such as infec-
tion, neutrophilc vascular disorders (certain subtypes of
vasculitis) or wound healing, for example. We demon-
strated previously that PAR2 agonist treatment affects sur-
face expression of b1 and b2 integrins by human
neutrophils (29). Thus, we hypothesized that PAR2 agonist
stimulation of endothelial cells as well as granulocytes may
influence migratory ability of the latter. To test this
PAR2 and human innate immunity
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hypothesis, we used an experimental system where both cell
types (granulocytes and HMEC-1 endothelial cells) were
exposed to PAR2 agonists during leukocyte migration. We
revealed that application of PAR2 activating serine prote-
ases (trypsin or mast cell tryptase) as well as a synthetic
PAR2 activating peptide (tcAP) leads to significant reduc-
tion in the number of neutrophils migrated via endothelial
monolayer in comparison with untreated control (Fig. 1).
The magnitude of this effect was very similar for all PAR2
agonists used in study – about 25 ± 4% of reduction (the
application of fMLP, which was used as positive control,
led to 60 ± 4% reduction) (Fig. 1). Neither treatment with
heparin nor PAR2 reverse peptide (tcRP) resulted in signifi-
cant changes of neutrophil transendothelial migration
(Fig. 1).
Proteinase-activated receptor-2 agonist stimulation
prolongs human neutrophil survival in vitro
Human neutrophils are known to have a relatively short
half-life in the circulation [(reviewed in Ref. (30)]. The life
span of mature neutrophils may be extended in vitro by
incubation with either pro-inflammatory cytokines or with
bacterial products (38). Therefore, we investigated whether
treatment of isolated human neutrophils with PAR2 agon-
ists might extend neutrophil survival in vitro. Indeed,
PAR2-tcAP stimulation of human neutrophils from healthy
donors prolonged cell survival (estimated using population
of early apoptotic cells in Annexin V ⁄ propidium-iodide
assay) (Fig. 2). At 6 h after PAR2-tcAP application, the
amount of early apoptotic neutrophils was 47 ± 4% lower
as compared with untreated control cells. However, this
trend was still detectable up to 12 h after agonist treatment.
Moreover, application of trypsin in a concentration of
10)7 m also resulted in extended neutrophil survival in vitro.
At 6 h after trypsin stimulation, the amount of early
apoptotic cells becomes 21 ± 4% lower as compared with
the amount of early apoptotic cells in untreated control
samples. Application of trypsin or PAR2-tcAP did not
change significantly the number of neutrophils in the pop-
ulation of late apoptotic and necrotic cells (data not
shown). Stimulation of cultured neutrophils with scram-
bled PAR2-tcRP (negative control) did not affect neutrophil
apoptosis in vitro (Fig. 2).
Effects of IFNc stimulation on PAR2 expression
on the human neutrophil cell surface
Previously, Nystedt et al. (39) reported that stimulation of
cultured human umbilical vein endothelial cells (HUVEC)
with such pro-inflammatory cytokines as TNFa or IL-1a
elevated the expression of PAR2 mRNA in these cells. IFNc
is an immune cell produced cytokine with dual properties
(pro- and anti-inflammatory) and has an ability to modu-
late the level of certain pro-inflammatory cytokines (TNFa,
IL-1a) (40). Therefore, we were interested whether IFNc
stimulation may also affect PAR2 expression on human neu-
trophil cell surface. At 6 h after IFNc application, the
amount of PAR2 positive cells increases by 45 ± 4% as
Reduction of neutrophil migration
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Figure 1. Proteinase-activated receptor-2 (PAR2) agonists reduce
transendothelial migration of human neutrophils from healthy
volunteers. The number of granulocytes used for assay (input) was
always constant in all experiments and for each sample (2 · 106 cells).
The average number of neutrophils migrated in control sample was
5.96 · 105 ± 0.8 · 105 cells. In our experimental system, both cell types
[human neutrophils and human microvascular endothelial cells
(HMEC-1)] were stimulated with PAR2 agonists (see ‘Materials and
Methods’ for details). Stimuli were used in concentrations: tryptase and





30 lg ⁄ ml; N-formylmethionyl-leucyl-phenylalanine (fMLP) 5 nm. Four
independent experiments were performed, each in triplicates. Results are
presented as an average effect of agent application at neutrophil













































Figure 2. Agonists of proteinase-activated receptor-2 (PAR2) prolong
survival of cultured human neutrophils from healthy volunteers. No
induction of apoptosis was performed. Presented data are relative
where as 100% is considered the number of early apoptotic cells in
untreated control samples. Application of stimuli did not change
significantly the number of neutrophils in populations of late apoptotic
and necrotic cells. Results are presented as an average amount of early
apoptotic cells relatively to untreated control sample in per
cents ± SEM. White filled (h) boxes represent the data of PAR2-tcAP
(10)4 m) treated; grey filled ( ) boxes – trypsin (10)7 m) treated; black
filled ( ) boxes – PAR2-tcRP (10
)4
m) treated samples. *P < 0.05,
** P < 0.01. Six independent experiments were performed.
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compared with unstimulated neutrophils. However, the
up-regulation of the mean fluorescence intensity (MFI)
remains less pronounceable (increased by 33 ± 3% as com-
pared with the level of untreated control) (Fig. 3a). The sit-
uation changes at 12 h after IFNc application (Fig. 3b). The
number of PAR2-positive neutrophils remains very similar
to the one of untreated control cells (increased by only
18 ± 5% as compared with untreated cells). Nonetheless,
the up-regulation of MFI was significant (MFI increases by
98 ± 9% as compared with untreated control) (Fig. 3b).
Simultaneous application of PAR2 agonist and
interferon c enhances IFNc-induced expression of
FccRI (CD64) at neutrophil cell surface
Despite granulocytes from healthy individuals are known to
express CD64 at very low level, its display is induced by
stimulation of neutrophils with IFNc (31). Therefore, we
investigated whether co-administration of PAR2 agonist
and IFNc might enhance the known IFNc-induced effect at
CD64 display on neutrophil cell surface. Indeed, our results
suggest that the treatment of human neutrophils with both
agents (PAR2-tcAP and IFNc) leads to stronger up-regula-
tion of CD64 on neutrophil cell surface than stimulation
with IFNc alone (Fig. 4a,b). The effect of PAR2-tcAP and
IFNc co-application reaches its maximum at 12 h, but it
already becomes significant at 6 h after agonist treatment
(Fig. 4a). At 12 h after agonist application, this effect is
characterized by up-regulation of MFI (increased by
41 ± 9% as compared with cells treated with IFNc alone)
as well as of the number of positive neutrophils (up-regu-
lated at 90 ± 8% as compared with neutrophils stimulated
by IFNc alone) (Fig. 4b). Of note, co-stimulation of cul-












































Figure 3. Interferon (IFN)c stimulation of human neutrophils from
healthy volunteers up-regulates proteinase-activated receptor-2 (PAR2)
expression on the cell surface. Neutrophils were treated with IFNc
(200 U ⁄ ml) and analysed at 6 h (a) or 12 h (b) after stimulation. PAR2
positive cells are gated. Left border of the gate was always set the way
that not more than 1% cells of secondary antibody control sample
were included inside the gate region. The percent of PAR2-positive cells
in untreated control samples was 44.9 ± 8% for 6 h, and 52.8 ± 6%
for 12 h. The mean fluorescence intensity (MFI) absolute value of PAR2
positive cells in untreated control was 52.2 ± 11 for 6-h samples, and












































































Figure 4. Simultaneous application of proteinase-activated receptor-2
(PAR2) agonist and interferon (IFN)c enhances IFNc-induced expression
of CD64 expression at human neutrophil cell surface. Neutrophils were
isolated from healthy volunteers. The graph (a) represents changes in
CD64 cell surface expression after stimulation of cells with PAR2-
tcAP 10)4 m ; PAR2-tcRP 10
)4
m ; IFNc 200 U ⁄ ml h; IFNc
(200 U ⁄ ml) + PAR2-tcAP(10)4 m) ; IFNc (200 U ⁄ ml) + PAR2-
tcRP(10)4 m) . There were no significant changes in CD64 expression
after stimulation of neutrophils with either PAR2-tcAP or PAR2-tcRP (the
respective columns at the graph have very small value). Results are
presented as an average effect of agent application at the number of
CD64-positive neutrophils as compared with untreated control samples
(expressed in percents) ±SEM. *P < 0.05, **P < 0.01. Additionally, the
difference in average effects between samples stimulated with IFNc
alone and co-stimulated with PAR2-tcAP and IFNc was analysed.
Statistical significance of such difference is marked #P < 0.05,
###P < 0.001. Four independent experiments were performed.
Histogram shows CD64 surface expression at 12 h after stimuli
application (b). Gated cells are CD64-positive cells.
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(negative control) did not affect neutrophil CD64 expres-
sion as compared with cells stimulated by IFNc alone
(Fig. 4a). Stimulation of human neutrophils either by
PAR2-tcAP or PAR2-tcRP alone also did not affect CD64
cell surface display (Fig. 4a).
Changes of PAR2 cell surface display on
neutrophils of septic patients
Our in vitro data indicate that PAR2 agonists reduce migra-
tion of neutrophils via endothelium and also prolong neu-
trophil survival, therefore, potentially may promote an
increase of neutrophil count in circulation. We also dem-
onstrated that, PAR2 agonists acting together with IFNc,
significantly enhance the effect of latter at CD64 expression
on neutrophils, and these results indicate the involvement
of PAR2 activation in phagocytosis. Together, our data sug-
gest that neutrophil PAR2 could be involved in the patho-
genesis of human diseases, where phagocytes are in contact
with pathogens in the blood flow. One of such diseases is
sepsis. Therefore, we tested whether the level of neutrophil
PAR2 cell surface expression might change in septic
patients. Indeed, our data clearly demonstrate an increased
(about 82% of up-regulation as compared with healthy vol-
unteers) PAR2 expression on neutrophils of septic patients
(Fig. 5). Thus, PAR2 may contribute to the modulation of
neutrophil function during human sepsis.
Discussion
In a recent study (29), we demonstrated the ability of
PAR2 agonists to up-regulate neutrophil cytokine produc-
tion and motility in 3-D collagen lattices. The main goal of
the present study was to further explore the role of PAR2
on neutrophils with special regard to its capability to mod-
ulate neutrophil-endothelial interactions.
Our previous results were predominantly associated with
a scenario in which the activation of neutrophil PAR2 took
place in the extracellular matrix, i.e. after cell migration
into the extravascular compartment. However, PAR2 activa-
tion on neutrophils in the vascular compartment (before
transendothelial migration) cannot be completely excluded,
as various natural PAR2 agonists are released within blood
vessel. Among such agonists are endothelial-derived trypsin
and factor VII ⁄ Xa, for example (41–43). Therefore, in the
current study, we focused on the effects of PAR2 agonists,
which are especially important for leukocyte biology in the
blood flow. We revealed that PAR2 agonists down-regulate
trans-endothelial migration of human granulocytes in vitro.
Moreover, PAR2 agonists extended neutrophil life span and
enhanced the IFNc-induced FccRI (CD64) receptor expres-
sion on human neutrophils. The increase in CD64 expres-
sion is known to be associated with an enhancement of
antibody-dependent cellular cytotoxicity (ADCC) and
phagocytosis (31,44). Consequently, this ability of PAR2
agonists to enhance IFNc effects strongly indicates that
co-activation of PAR2 and cellular cytokine receptors may
affect the progress of acute inflammatory diseases. This idea
is linked to our first-time observations that PAR2 and its
proteases may be involved in human diseases in vivo, as
demonstrated in septic patients. Our results clearly suggest
the involvement of PAR2 in neutrophil-endothelial interac-
tions by modulating transmigration and apoptosis of
human neutrophils.
Transendothelial migration of granulocytes is considered
as a key step in immune response to pathogens (45). How-
ever, uncontrolled adhesion to endothelium and recruit-
ment of neutrophils towards the site of inflammation may
lead to significant tissue damage and, therefore, to poor
prognosis for patient (46,47). Thus, only the accurate regu-
lation of granulocyte recruitment in extravascular compart-
ment promotes resolution of inflammation without serious
complications. Our in vitro data indicate the potential role
of serine proteases and their receptors in the regulation of
leukocyte transendothelial migration. Indeed, proteases
(trypsin and tryptase) as well as a PAR2 activating peptide
reduced the migration of human neutrophils via endothe-
lial monolayer. Therefore, at an early stage after stimula-
tion, PAR2 agonists and their receptor may represent an
additional system which controls leukocyte recruitment and
consequently modulates the intensity of immune response.
Delayed apoptosis of neutrophils migrated in extravas-
cular space can affect the progression of inflammatory
responses during infection. This effect is reached via a
reduced clearance of neutrophils from the inflamed tissues
and therefore via a risk of tissue injury by neutrophil gran-
ule contents (48). On the other hand, extended life of neu-
trophils in vascular compartment may be beneficial as it































Figure 5. An increased expression of PAR2 at the cell surface of
human neutrophils from septic patients. PAR2 display on human
neutrophil cell surface is up-regulated in septic patients (19 cases) as
compared with healthy volunteers (18 cases). The results are presented
as average in mean fluorescence intensity units ±SEM. **P < 0.01.
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immune response (31). Therefore, it was of importance to
note that PAR2 agonists (trypsin as well as activating pep-
tide) down-regulate human neutrophil apoptosis. Such an
effect of PAR2 agonists on neutrophil apoptosis together
with reduction of transendothelial migration may modulate
the amount of human nuetrophils in circulation at early
stages after stimulation.
CD64 is a high-affinity Fcc receptor, which is known to
be expressed only at a very low level by neutrophils from
healthy adults (31,49). However, IFNc stimulation or bacte-
rial infections are reported to induce the expression of
CD64 on neutrophils (50,51). The increase in CD64 display
appears to be associated with an enhancement of ADCC
and phagocytic activity of neutrophils (31,44). As we
showed in the current study, PAR2-tcAP stimulation alone
did not markedly affect CD64 expression on neutrophil cell
surface. However, co-application of PAR2 agonists together
with IFNc enhanced the effect of latter. Our data also indi-
cate that IFNc stimulation up-regulates PAR2 expression on
the cell surface of isolated human neutrophils. Therefore,
coordinated interactions between IFNc and PAR2 agonists
may represent a mechanism by which IFNc-induced protec-
tive effects could be enhanced during bacterial infection.
Sepsis in humans is known to be characterized by a state
of immunosuppression associated with shutdown of neu-
trophil phagocytic activity and some other neutrophil func-
tions (22). In attempt to reactivate monocyte and
neutrophil immune functions, IFNc-intravenous injections
were used in clinical trials in sepsis (28). Considering the
ability of PAR2 agonists to enhance one of IFNc-induced
protective effects on human neutrophils in vitro, we investi-
gated whether cell surface expression of neutrophil PAR2
may be affected during sepsis in human patients. Our study
clearly demonstrates the up-regulation of PAR2 on the neu-
trophil cell surface in septic patients. In accordance with
these findings, the potential role of the combined action of
PAR2 agonist and IFNc during human sepsis represents an
innovative field for further investigations.
Neutrophils are the most numerous cells of blood leuko-
cytes and represent the first line of the innate immune
defense against infection. Consequently, neutrophils need
to be recruited to the site of inflammation very rapidly.
During disease state, molecules exist which may support or
counteract this capability (52). Thus, proteases released by
endothelial cells, mast cells or neutrophils themselves may
be involved in the pathophysiology of cutaneous inflamma-
tion and sepsis in humans by affecting neutrophil apopto-
sis, transendothelial migration and Fcc receptor-mediated
phagocytosis. This may be of importance for the regulation
of neutrophil activity during infection including septic
conditions, inflammation as well as wound healing.
In conclusion, our data demonstrated that PAR2 agonists
are able to enhance the protective IFNc-induced effect on
neutrophil function. Moreover, PAR2 agonists (activating
serine proteases or peptides) and their receptor represent
an additional system which controls neutrophil transendo-
thelial migration and apoptosis in vitro. Thus, such system
may be involved in the changes of neutrophil-endothelial
interactions as well as in the enhancement of cytokine-
induced effects at neutrophil functions during inflamma-
tory or acute bacteria-induced pathologies in humans.
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